A Study to Evaluate Antimalarial Activity and Safety of MK-7602 in Healthy Adults (MK-7602-003) - Trial NCT06294912
Access comprehensive clinical trial information for NCT06294912 through Pure Global AI's free database. This Phase 1 trial is sponsored by Merck Sharp & Dohme LLC and is currently Recruiting. The study focuses on Malaria. Target enrollment is 42 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Merck Sharp & Dohme LLC
Timeline & Enrollment
Phase 1
Apr 18, 2024
Mar 24, 2025
Primary Outcome
Parasite reduction ratio (PRR48) (Parts 1 and 2),Parasite Clearance Half-life (PCt1/2) (Parts 1 and 2),Parasite Regrowth (Parts 1 and 2),Part 1 Single dose: Area Under the Concentration-Time Curve Extrapolated to Infinity (AUC0-inf) of MK-7602,Part 1 Single dose: Maximum Plasma Concentration (Cmax) of MK-7602,Part 1 Single dose: Concentration at 24 Hours (C24) of MK-7602,Part 1 Single dose: Time to Maximum Plasma Concentration (Tmax) of MK-7602,Part 1 Single dose: Elimination Half-life (t1/2) of MK-7602,Part 2 Multiple dose: Area Under the Curve Time 0 to End of the Dosing Interval (AUC0-tau) of MK-7602,Part 2 Multiple dose: Maximum Plasma Concentration (Cmax) of MK-7602,Part 2 Multiple dose: Time to Maximum Plasma Concentration (Tmax) of MK-7602,Part 2 Multiple dose: Elimination Half-life (t1/2) of MK-7602
Summary
The purpose of this study is to assess the antimalarial activity, pharmacokinetics, and
 safety of MK-7602 in healthy adults following Plasmodium falciparum (P. falciparum)
 infection.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06294912
Non-Device Trial